Metrics to compare | NYMXF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYMXFPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.7x | −0.4x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | 0.0x | 1.6x | 2.6x | |
Price / LTM Sales | 0.0x | 0.9x | 3.1x | |
Upside (Analyst Target) | 0.0% | 113.0% | 48.6% | |
Fair Value Upside | Unlock | 4.2% | 5.8% | Unlock |
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.